Advertisement

Reply to: Combination of brachytherapy and chemotherapy not superior to pelvic radiotherapy according to GOG-249

  • S. MarnitzEmail author
Letter to the Editor
  • 77 Downloads

Notes

Conflict of interest

S. Marnitz declares that he/she has no competing interests.

References

  1. 1.
    Marnitz S et al (2018) Evolution of adjuvant treatment in endometrial cancer-no evidence and new questions? Srahlenther Onkol.  https://doi.org/10.1007/s00066-018-1339-6 Google Scholar
  2. 2.
    Randall ME et al (2006) Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 24:36–44CrossRefGoogle Scholar
  3. 3.
    de Boer SM et al (2018) Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 19:295–309CrossRefGoogle Scholar
  4. 4.
    Matei D et al (2017) A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma. J Clin Oncol 35:5505CrossRefGoogle Scholar
  5. 5.
    Cancer Genome Atlas Research Network (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497(7447):67–73CrossRefGoogle Scholar
  6. 6.
    Stelloo E et al (2016) Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer—combined analysis of the PORTEC cohorts. Clin Cancer Res 22(16):4215–4224CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Medical Faculty, Department of Radiation Oncology, CyberKnife- and Radiation TherapyUniversity of CologneCologneGermany

Personalised recommendations